#TORRENT PHARMA DERMA PRODUCTS TORRENT#

Torrent Pharma bagged the Gold Trophy for IDMA Quality Excellence Award for its Formulations facility. Torrent Pharma, the flagship Company of Torrent Group is one of the leading. The API and formulations manufacturing facilities located at Indrad (Gujarat, India) got USFDA approval. Torrent Pharma recognized as the Most Promising Company of the Year at the 10th CNBC TV18 India Business Leader Awards 2014.ДЄcquired Elder PharmaвЂ™s Indentified Indian Branded Formulation Business in India and Nepal. Source: Torrent Pharmaceuticals Ltd: Leader in the pharmaceutical industry 2015 Torrent Pharma is the sole manufacturer of Insulin Formulations for Novo Nordisk in India since the early вЂ90s and has also set up a dedicated formulation and packaging facility for Insulin. A new facility is taking shape at Dahej SEZ in Western India, which will cater to the international markets. Encore group has approvals to export its products to US and Australia and has presence in countries such as Canada, China, Vietnam, Nepal, Thailand, Vietnam to name a few. The facilities are approved by USFDA, WHO, MHRA, TGA and other global regulatory bodies. The acquisition of derma business of Encore group provides Torrent Pharma access to global market also.

It has three world-class manufacturing facilities at Indrad (Gujarat), Baddi (Himachal Pradesh) and Sikkim. Torrent PharmaвЂ™s competitive advantage stems from its world-class manufacturing facilities, advanced R&D capabilities, extensive domestic network and a widespread global presence. Present invention also relates to a method of treating inflammatory bowel disease in a. Right from pioneering niche marketing in India to earning the sobriquet of вЂthe Company with the most first launchesвЂ™, Torrent Pharma has always remained ahead of its competition. Abstract: Present invention relates to a low dose pharmaceutical composition, preferably oral composition comprising therapeutically effective amount of (2-hydroxy-4-oxo-6,7,8,9-tetrahydro-4H,5H-10-thia-1,4a-diaza-benzoaazulene-3-carbonyl)-amino-acetic acid (compound A) in the range of 2.5 mg to 60 mg. It has also forayed into the therapeutic segments of nephrology and oncology while also strengthening its focus on gynecology and pediatric segments. It is a dominant player in the therapeutic areas of cardiovascular (CV) and central nervous system (CNS) and has achieved significant presence in gastro-intestinal, diabetology, anti-infective and pain management segments.

Torrent Pharma, the flagship company of Torrent Group, is ranked amongst the top pharma companies of India.

Torrent Pharma Derma Products